Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands are disclosed. For example, heterobifunctional inhibitors of E-selectin and galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.
Type:
Application
Filed:
November 7, 2023
Publication date:
May 9, 2024
Applicant:
GLYCOMIMETICS, INC.
Inventors:
John L. MAGNANI, John M. PETERSON, Arun K. SARKAR, Yusufbhai U. VOHRA, Indranath GHOSH, Jason NOGUEIRA
Abstract: A process is provided for the synthesis of an intermediate which is useful in the synthesis of E-selectin inhibitors. Also provided are useful intermediates obtained from the process.
Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, E-selectin antagonists are described and pharmaceutical compositions comprising at least one of the same.
Type:
Grant
Filed:
November 9, 2021
Date of Patent:
January 23, 2024
Assignee:
GLYCOMIMETICS, INC.
Inventors:
John L. Magnani, John M. Peterson, Arun K. Sarkar, Yusuf U. Vohra, Myung-Gi Baek
Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of galectin-3 to ligands are disclosed. For example, inhibitors of galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.
Type:
Grant
Filed:
December 26, 2019
Date of Patent:
January 16, 2024
Assignee:
GLYCOMIMETICS, INC.
Inventors:
John L. Magnani, John M. Peterson, Arun K. Sarkar, Yusufbhai U. Vohra, Indranath Ghosh, Jason Nogueira
Abstract: Methods for treating or inhibiting cancer and/or one or more related conditions by administering to a subject in need thereof an effective amount of a compound of Formula (I) a prodrug thereof or a pharmaceutically acceptable salt of any of the foregoing. For example, methods for treating AML, MDS, neutropenia, and/or mucositis comprising administering a pharmaceutical composition comprising a compound of Formula (I) are described.
Type:
Application
Filed:
June 7, 2023
Publication date:
December 28, 2023
Applicant:
GlycoMimetics, Inc.
Inventors:
Helen M. THACKRAY, Henry H. FLANNER, Curt D. WOLFGANG
Abstract: Methods are disclosed for the mobilization of marrow infiltrating cells (MILs) using E-selectin antagonists for the treatment of disorders such as cancer. Methods for treating or preventing cancers using MILs mobilized by E-selectin antagonists are further disclosed.
Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands are disclosed. For example, heterobifunctional inhibitors of E-selectin and galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.
Type:
Grant
Filed:
December 26, 2019
Date of Patent:
December 19, 2023
Assignee:
GLYCOMIMETICS, INC.
Inventors:
John L. Magnani, John M. Peterson, Arun K. Sarkar, Yusufbhai U. Vohra, Indranath Ghosh, Jason Nogueira
Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, highly potent multimeric E-selectin antagonist are dessorbed and pharmaceutical compositions comprising at least one of the same.
Type:
Application
Filed:
July 19, 2023
Publication date:
November 16, 2023
Applicant:
GLYCOMIMETICS, INC.
Inventors:
John L. MAGNANI, John M. PETERSON, Myung-Gi BAEK
Abstract: E-selectin ligands which are useful for the synthesis of E-selectin ligand-bearing carriers, wherein said E-selectin ligand-bearing carriers are directly or indirectly linked to or associated with at least one therapeutic agent, diagnostic agent, imaging agent, or radiopharmaceutical are described herein.
Type:
Application
Filed:
September 17, 2021
Publication date:
November 16, 2023
Applicant:
GLYCOMIMETICS, INC.
Inventors:
John L. MAGNANI, John M. PETERSON, William E. FOGLER, Myung-Gi BAEK
Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, highly potent multimeric E-selectin antagonist are desorbed and pharmaceutical compositions comprising at least one of the same.
Type:
Grant
Filed:
June 15, 2021
Date of Patent:
October 10, 2023
Assignee:
GlycoMimetics, Inc.
Inventors:
John L. Magnani, John M. Peterson, Myung-Gi Baek
Abstract: Methods are disclosed for the mobilization of marrow infiltrating cells (MILs) using E-selectin antagonists for the treatment of disorders such as cancer. Methods for treating or preventing cancers using MILs mobilized by E-selectin antagonists are further disclosed.
Abstract: Methods for treating or inhibiting cancer and/or one or more related conditions by administering to a subject in need thereof an effective amount of a compound of Formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing. For example, methods for treating AML, MDS, neutropenia, and/or mucositis comprising administering a pharmaceutical composition comprising a compound of Formula (I) are described.
Type:
Grant
Filed:
March 4, 2019
Date of Patent:
July 25, 2023
Assignee:
GlycoMimetics, Inc.
Inventors:
Helen M. Thackray, Henry H. Flanner, Curt D. Wolfgang
Abstract: Methods for treating a cancer (such as, e.g., acute myeloid leukemia) comprising administering to a subject (such as, e.g., a subject who has acquired resistance to a therapy comprising at least one antineoplastic agent and/or at least one hypomethylating agent) at least one E-selectin antagonist, wherein the subject is further administered at least one antineoplastic agent (such as, e.g., venetoclax) and/or at least one hypomethylating agent are disclosed.
Type:
Application
Filed:
June 11, 2021
Publication date:
July 13, 2023
Applicant:
GLYCOMIMETICS, INC.
Inventors:
John L. MAGNANI, William E. FOGLER, Theodore SMITH
Abstract: CD33 ligands which are useful for the synthesis of CD33 ligand-bearing carriers, wherein said CD33 ligand-bearing carriers are directly or indirectly linked to or associated with at least one anti-cancer agent, are described herein. Uses of said CD33 ligand-bearing carriers for treating and/or preventing a disease, disorder, or condition such as acute myeloid leukemia (AML) are also described.
Type:
Application
Filed:
April 30, 2021
Publication date:
June 1, 2023
Applicant:
GLYCOMIMETICS, INC.
Inventors:
John L. MAGNANI, John M. PETERSON, Indranath GHOSH, Myung-Gi BAEK
Abstract: CD33 ligands which are useful for the synthesis of CD33 ligand-bearing carriers, wherein said CD33 ligand bearing carriers are directly or indirectly linked to or associated with at least one anti-cancer agent, are described herein. Uses of said CD33 ligand-bearing carriers for treating and/or preventing a disease, disorder, or condition such as acute myeloid leukemia (AML) are also described. The ligands have formula (I) below.
Type:
Application
Filed:
April 30, 2021
Publication date:
June 1, 2023
Applicant:
GLYCOMIMETICS, INC.
Inventors:
John L. MAGNANI, John M. PETERSON, Indranath GHOSH
Abstract: Methods for treating cancer (such as, e.g., acute myelogenous leukemia), enhancing maintenance of normal hematopoiesis in bone marrow, and/or mobilizing leukemia blasts in a subject in need thereof comprising administering to the subject at least one FLT3 inhibitor and at least one inhibitor chosen from E-selectin inhibitors, CXCR4 inhibitors, and heterobifunctional inhibitors of E-selectin and CXCR4.
Abstract: Methods for treating diseases, disorders, and/or conditions associated with COVID-19 comprising administering at least one E-selectin antagonist and/or composition comprising the same are disclosed. Also disclosed are compounds, compositions, and methods for treating patients with acute respiratory distress syndrome.
Type:
Application
Filed:
March 26, 2021
Publication date:
May 11, 2023
Applicant:
GLYCOMIMETICS, INC.
Inventors:
John L. MAGNANI, William E. FOGLER, Armand F. GIRARD
Abstract: Compositions and methods for the treatment of diseases, disorders, and/or conditions associated with the increased regulatory T lymphocyte cell function, comprising the administration of T-cell checkpoint inhibitors in combination with E-selectin inhibitors, C-X-C Motif Chemokine Receptor 4 (CXCR4) receptor inhibitors, and/or heterobifunctional inhibitors that comprise at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor, are disclosed.
Abstract: Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.
Type:
Application
Filed:
April 20, 2022
Publication date:
March 30, 2023
Applicant:
GLYCOMIMETICS, INC.
Inventors:
John L. MAGNANI, Arun K. SARKAR, Myung-Gi BAEK, Frank E. ANDERSON, III, Yanhong LI
Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of galectin-3 to ligands are disclosed. For example, inhibitors of galectin-3 are described and pharmaceutical compositions comprising at least one such agent are described.
Type:
Application
Filed:
December 23, 2020
Publication date:
March 23, 2023
Applicant:
GLYCOMIMETICS, INC.
Inventors:
John L. MAGNANI, John M. PETERSON, Yusuf U. VOHRA, lndranath GHOSH, Jason NOGUEIRA, Arun K. SARKAR, Debatosh MAJUMDAR